Biotech rally mints huge profits for hedge funds
Wave of M&A fuels rally as big pharma groups hunt for blockbusters ahead of patent cliff
Related reading
Big pharma’s scramble over the patent cliff will be costly
Groups will need to buy mature biotechs to replace revenue lost to generic competitors
Tech rally hands hedge funds biggest gains since 2020
Industry posts 5% returns in April as stocks including Intel, Alphabet and AMD soar
UK biotech keeps selling itself to America
A shortage of late-stage capital pushes the biggest prizes into US hands
Merck nears $6bn biotech deal to boost cancer drug pipeline
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
Bullish investors pile into stocks as cash levels sink to record low
Fund managers most optimistic since 2021 despite worries over tech valuations, Bank of America survey shows
Merck transforms itself through dealmaking as clock ticks on top-selling drug
Acquisitions fuel pharma group’s evolution as it prepares to lose patent protection on cancer drug Keytruda